The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Jim Cramer Weighs In On Carnival, Canadian Pacific Railway And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Fulgent Genetics, Inc. (NASDAQ: FLGT) is a "mystery" to him. With the company doing quite well, he considers it a very good company.
Fulgent Genetics Reports Confirmation Of Ability To Detect Omicron Variant With PCR Tests For COVID-19
Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Helio Health, Fulgent Genetics Announce Late-Breaking Performance Data Of HelioLiver For Early Liver Cancer Detection
Helio Health ("Helio") and its commercial partner, Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent") today announced new data at AASLD demonstrating the
Fulgent Genetics’s Return on Invested Capital Overview
Pulled from Benzinga Pro data, Fulgent Genetics (NASDAQ:FLGT) posted Q2 earnings of $98.90 million, an increase from Q1 of 62.95%. Sales dropped to $153.62 million, a 57.26% decrease between quarters.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.